SCHEMBL9917216

SCHEMBL9917216

Cc1ccc(-c2ccc(-c3ccc4c(c3)oc3cc(-c5ccccc5)ccc34)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ POLB P06746 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ MAOB P27338 6/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ CCNC P24863 1/20 0.46
▸ CDK8 P49336 1/20 0.46
▸ TNKS2 Q9H2K2 2/20 0.44
▸ TNKS O95271 1/20 0.44
▸ PARP1 P09874 1/20 0.44
▸ PARP2 Q9UGN5 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17523443 1.00 HPGD (0.48) HPGDNPC1RAB9APOLBSMN1; SMN2
SCHEMBL9917226 0.94 MAOB (0.49) HPGDNPC1RAB9APOLBSMN1; SMN2
SCHEMBL17427794 0.92 MAOB (0.52) HPGDNPC1RAB9ASMN1; SMN2MAOB
SCHEMBL9917159 0.91 MAOB (0.58) HPGDNPC1RAB9ASMN1; SMN2MAOB
SCHEMBL9917209 0.91 MAOB (0.58) HPGDNPC1RAB9ASMN1; SMN2MAOB
SCHEMBL17523446 0.91 MAOB (0.58) HPGDNPC1RAB9ASMN1; SMN2MAOB
SCHEMBL26519285 0.90 NPC1 (0.47) HPGDNPC1RAB9APOLBSMN1; SMN2
SCHEMBL10110901 0.90 PRKDC (0.47) HPGDSMN1; SMN2MAOBL3MBTL1GAA
SCHEMBL9917138 0.90 MAOB (0.54) HPGDNPC1RAB9ASMN1; SMN2MAOB
SCHEMBL9917188 0.90 MAOB (0.54) HPGDNPC1RAB9ASMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355218-B2 Aromatic amine derivatives and organic electroluminescent elements using same IDEMITSU KOSAN CO., LTD. (JP) 2019-07-16 — — US disclosed
US-20170162790-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2017-06-08 — — US disclosed
US-9614160-B2 Aromatic amine derivatives and organic electroluminescent elements using same IDEMITSU KOSAN CO., LTD. (JP) 2017-04-04 — — US disclosed
US-20160064669-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-03-03 — — US disclosed
US-9260390-B2 Aromatic amine derivatives and organic electroluminescent elements using same IDEMITSU KOSAN CO., LTD. (JP) 2016-02-16 — — US disclosed
US-20120146014-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170162790-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME RER1, NR4A1, REL HPGD 4080/4885NPC1 4520/4885RAB9A 738/4885
US-10355218-B2 Aromatic amine derivatives and organic electroluminescent elements using same RER1, NR4A1, REL HPGD 4079/4885NPC1 4526/4885RAB9A 745/4885
US-20120146014-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME PNMT, TYR, AOC2 HPGD 3636/4885NPC1 3475/4885RAB9A 1734/4885
US-20160064669-A1 AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME PNMT, TYR, AOC2 HPGD 3636/4885NPC1 3475/4885RAB9A 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback